Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | EVP, Business Development | August 09, 2024 | August 13, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date August 09, 2024 · Filed August 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 8,848 |
Last balance in matching sequence
After 2024-08-09 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2024-08-09 · Exercise / conversion · Acquired 12,913 · Balance 12,913 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Row 2 · 2024-08-09 · Sale · Disposed 4,065 · Balance 8,848 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2024. F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 38,739 |
Reported balance
After 2024-08-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-08-09 · Exercise / conversion · Disposed 12,913 · Balance 38,739 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5: Restricted share units were granted on August 9 ,2023, with 12,913 vesting on each of August 9, 2024, August 9, 2025, August 9, 2026 and August 9, 2027. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2024.
F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
F5: Restricted share units were granted on August 9 ,2023, with 12,913 vesting on each of August 9, 2024, August 9, 2025, August 9, 2026 and August 9, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 09, 2024 Filed Aug 13, 2024 20:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 12,913 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-096182 · ownership.xml · derivative · entry 3 Grant Angus · CIK 0001988830 · EVP, Business Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,739 Underlying: Ordinary Shares · 12,913 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on August 9 ,2023, with 12,913 vesting on each of August 9, 2024, August 9, 2025, August 9, 2026 and August 9, 2027. F5 · derivative.expiration_date: Restricted share units were granted on August 9 ,2023, with 12,913 vesting on each of August 9, 2024, August 9, 2025, August 9, 2026 and August 9, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 20:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 4,065 | $17.28 | $70,243.20 |
DisclosureSEC source: 0000950170-24-096182 · ownership.xml · nonDerivative · entry 2 Grant Angus · CIK 0001988830 · EVP, Business Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,848 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2024. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 20:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 12,913 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-096182 · ownership.xml · nonDerivative · entry 1 Grant Angus · CIK 0001988830 · EVP, Business Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:30 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 52,083 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026019 · ownership.xml · derivative · entry 1 Grant Angus · CIK 0001988830 · EVP, Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,083 Underlying: Ordinary Shares · 52,083 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 13,020 vesting on each of March 4, 2025, March 4, 2026 and March 4, 2027, and 13,023 vesting on March 4, 2028. F2 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 13,020 vesting on each of March 4, 2025, March 4, 2026 and March 4, 2027, and 13,023 vesting on March 4, 2028. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 09, 2023 Filed Aug 10, 2023 20:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 51,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-045292 · doc4.xml · derivative · entry 1 Grant Angus · CIK 0001988830 · EVP, Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,652 Underlying: Ordinary Shares · 51,652 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on August 9, 2023, with 12,913 vesting on each of August 9, 2024, August 9, 2025, August 9, 2026 and August 9, 2027. F2 · derivative.expiration_date: Restricted share units were granted on August 9, 2023, with 12,913 vesting on each of August 9, 2024, August 9, 2025, August 9, 2026 and August 9, 2027. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.